WO2004106535A2 - Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles - Google Patents
Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles Download PDFInfo
- Publication number
- WO2004106535A2 WO2004106535A2 PCT/US2004/016855 US2004016855W WO2004106535A2 WO 2004106535 A2 WO2004106535 A2 WO 2004106535A2 US 2004016855 W US2004016855 W US 2004016855W WO 2004106535 A2 WO2004106535 A2 WO 2004106535A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scatter
- orp
- cells
- light
- angle
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 117
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000000684 flow cytometry Methods 0.000 title abstract description 17
- 238000000423 cell based assay Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 113
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 49
- 210000004698 lymphocyte Anatomy 0.000 claims description 40
- 229910052737 gold Inorganic materials 0.000 claims description 29
- 239000010931 gold Substances 0.000 claims description 29
- 230000008033 biological extinction Effects 0.000 claims description 20
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 17
- 102000006240 membrane receptors Human genes 0.000 claims description 17
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 15
- 229910052709 silver Inorganic materials 0.000 claims description 15
- 239000004332 silver Substances 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 230000009870 specific binding Effects 0.000 claims description 11
- 239000003093 cationic surfactant Substances 0.000 claims description 10
- 238000013459 approach Methods 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 6
- 238000000149 argon plasma sintering Methods 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 4
- MTCUAOILFDZKCO-UHFFFAOYSA-N Decamethonium Chemical compound C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C MTCUAOILFDZKCO-UHFFFAOYSA-N 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229950000405 decamethonium Drugs 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229910010271 silicon carbide Inorganic materials 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 4
- 210000004970 cd4 cell Anatomy 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 abstract description 9
- 238000004166 bioassay Methods 0.000 abstract description 3
- 238000009739 binding Methods 0.000 description 23
- 230000027455 binding Effects 0.000 description 21
- 210000003714 granulocyte Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 9
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229950007870 hexadimethrine bromide Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 239000004065 semiconductor Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000001427 coherent effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000008279 sol Substances 0.000 description 5
- 108010041397 CD4 Antigens Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000005653 Brownian motion process Effects 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000005537 brownian motion Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003126 immunogold labeling Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000000707 layer-by-layer assembly Methods 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JPZYXGPCHFZBHO-UHFFFAOYSA-N 1-aminopentadecane Chemical compound CCCCCCCCCCCCCCCN JPZYXGPCHFZBHO-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910018830 PO3H Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 101000930463 Sus scrofa Albumin Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000012124 rapid diagnostic test Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1425—Optical investigation techniques, e.g. flow cytometry using an analyser being characterised by its control arrangement
- G01N15/1427—Optical investigation techniques, e.g. flow cytometry using an analyser being characterised by its control arrangement with the synchronisation of components, a time gate for operation of components, or suppression of particle coincidences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
Definitions
- This invention relates to the field of biological assays where cells can be classified and quantified using flow cytometry and other optical instrumentation.
- the present invention uses the combination of the inherent, multi-angle light scatter from cells and the multi-angle light scatter from small particles that are selectively bound to surface molecules that are characteristic of the cell to identify and quantify cells in liquid suspension.
- the present invention uses methods of signal enhancement from light scatter particle labels that make the assay simple to use and inexpensive to manufacture, and novel flow cytometry apparatus that combines the particle label multi- angle light scatter signal with the inherent light scatter signal from the cell to positively identify and quantify the cell type.
- the invention uses particle materials that exhibit abnormally high light scattering efficiencies at certain "resonance wavelengths" (Optically Resonant Particles, ORP's) (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.). This resonance can greatly enhance the signal strength and enable a more sensitive cell identification assay. Unfortunately, these resonance wavelengths and available laser wavelengths are not always the same.
- the invention teaches a method of using ORP size to "tune" the resonance wavelength and strength of the resonance simultaneously to an optimum relative to the laser wavelength.
- the present invention relates to a method for the detection of an Optically Resonant Particle (ORP) by light scattering comprising the simultaneous optimization of the resonance wavelength and strength of resonance of the ORP to the laser excitation wavelength, whereby the resonance wavelength can be modified by increasing or decreasing the size of the ORP.
- ORP Optically Resonant Particle
- the present invention teaches a method of chemically accelerating the particle binding reaction to produce a detectable signal on a light scatter flow cytometer without centrifuging or "vortex” mixing the sample and reagent.
- Surface charge must be maintained in order to store a colloidal suspension for later use, but when this particle surface charge and the cell surface charge are of the same sign, then mechanical means such as centrifugation or manual "vortex” mixing have been used to force the particles and cells into contact.
- the method of the present invention relies on changing the surface charge characteristics of the particle and the cells in the sample by chemical means that are low cost and do not rely on the manual skill of the operator.
- the present invention relates to a method of decreasing the Coulombic forces between cell surface receptors and ORP's comprising the treatment of a sample containing cell surface receptors and ORP's with a cationic surfactant, wherein the cationic surfactant can be selected from the group consisting of decamethonium bromide, polydiallyldimemylammonium chloride and hexadecyltrimethylammonium bromide.
- the present invention teaches multi-angle light scatter flow cytometry apparatus that combines light scatter from the cell itself with light scatter signal from the particles that are bound to the cell surface to make Boolean logic judgements as to the biological identity of cells, and count only those that satisfy certain logical conditions
- Light scatter angles not sensitive to ORP's but otherwise sensitive to the inherent light scatter properties of cells are used to gate a flow cytometer on certain classes cells and light scatter angles sensitive to ORP's are used to identify and quantify sub-classes of said classes of cells.
- the present invention relates to a method for the identification and quantification of cells using a flow cytometer that employs the combination of inherent, multi-angle light scatter from cells and multi-angle light scatter from Optically Resonant Particles (ORP's) conjugated to cell specific binding compounds that selectively bind to surface structures characteristic of specific cells.
- ORP's Optically Resonant Particles
- CD4 positive human T- lymphocytes are identified and quantified in a whole blood sample.
- the light scatter signal from colloidal gold particles is optimized for maximum strength by size selection according to the laser wavelength used for detection.
- the present invention uses a simple assay that is inexpensive to automate and inexpensive to manufacture.
- the invention uses reagents that have an inherently low manufacturing cost while providing a strong signal that can be analyzed automatically without the need for a skilled flow cytometry operator exercising human judgment to separate the signal from background.
- Applications for the present invention include AIDS antiretroviral therapy monitoring in resource poor parts of the world and in remote public health centers in the industrialized world.
- Figure 1 contains diagrammatic representations of optical resonance for 40nm gold particles and 40nm silver particles in colloidal suspension.
- Figure 2 is a diagrammatic representation of tuning an optical resonance to a longer wavelength by increasing particle size.
- Figure 3 is a bar graph representation of light absorption from gold particles as a function of particle size.
- Figure 4 is a schematic illustration of a multi-angle light scatter flow cytometer; including sensors for extinction (EXT), low angle forward scatter (FSL), high angle forward scatter (FSH) and right angle scatter (RAS).
- Figure 5 represents the results of light scatter flow cytometric analysis with a semiconductor diode laser at a wavelength of 635nm for gold particles with sizes of 40nm (a), 80nm (b) and lOOnm (c).
- Figure 6 is a diagrammatic representation of an absorption spectrum of 50 ran silver colloids with resonance peak at 423nm.
- Figure 7 are diagrammatic representations of the comparative resolution of CD4+ lymphocyte clusters, (a) after 3 hour incubation at 37 degrees centigrade without accelerant, and (b) after a 5 minute incubation at 37 degrees centigrade with 0.1% hexadimethrine bromide.
- Figure 8 are diagrammatic representations of comparative positions of lymphocyte clusters (a) using FSH versus FSL with a nonbonding control reaction and (b) using FSH versus FSL when anti CD4 conjugated colloidal gold binds to the lymphocyte surface.
- Figure 9 are diagrammatic representations of comparative positions of lymphocyte clusters (a) using FSH versus TOL with a nonbonding control reaction with colloidal gold and (b) using FSH versus TOL when anti CD4 conjugated colloidal gold binds to the lymphocyte surface.
- FigurelO are diagrammatic representations of plots of RAS versus EXT; wherein (a) granulocytes are in the cluster to the upper right, monocytes are in the cluster to the left of the granulocytes, and lymphocytes are in one cluster below the monocytes and granulocytes in the absence of colloidal gold binding; and (b) in the presence of anti-CD4 conjugated colloidal gold binding there are two lymphocyte clusters instead of one, the CD4 positive lymphocytes that are labeled with colloidal gold are in the right hand lymphocyte cluster.
- Figure 11 is a diagrammatic representation of a plot of RAS versus EXT; wherein abnormal granulocyte cluster interferes with non-gated CD4 positive lymphocyte counting.
- Figure 12 are diagrammatic representations of plots illustrating (a) gating lymphocytes by FSH versus TOF; (b) interference between CD4 lymphocytes and abnormal granulocytes in an un-gated dot plot by RAS versus EXT; and (c) no interference using gated dot plot by RAS versus EXT.
- This invention relates to the field of biological assays where cells can be classified and enumerated using flow cytometry optical instrumentation.
- the invention combines information from multi-angle, light scatter from the cell itself and multi-angle light scatter from small, optically resonant particles that are selectively bound to surface molecules on the cell to carry out classification and enumeration.
- This light scatter method enables an instrumentation system that is simple to use, inexpensive to build, and mechanically robust; making it suitable for use in remote clinical environments.
- the present invention uses small particles that are chemically pre-conjugated to molecules, such as antibodies, that bind selectively to sites on the surface of cells.
- the characteristic light scatter pattern of the cell is modified by the bound particles and this modification can be detected by the use of a microscope, a flow cytometer, a spectrophotometer or other similar optical instrumentation.
- Flow cytometry is the preferred embodiment of the present invention.
- the amount of light scattered or absorbed by a particle is, in part, proportional to its geometric cross-sectional area, G.
- G ⁇ a , where a is the particle radius.
- the amount of light scattered or absorbed is a function of wavelength.
- Most particles have real and imaginary parts of the refractive index that are not in themselves strong functions of wavelength. Under these common conditions, the wavelength dependence for scattering and absorption is simple. Scattering is proportional to ⁇ "4 and absorption is proportional to ⁇ _1 .
- the resonance wavelength and relative strength of the resonance are also functions of the size of the particle. As the particle size approaches zero the resonance wavelength approaches a minimum value and a maximum relative strength that is dependent on the particle material.
- Examples of resonant particle materials and their associated minimum resonance wavelengths are aluminum at ⁇ 200nm (ultraviolet), silver at ⁇ 400nm (visible), gold at ⁇ 530nm (visible), and silicon carbide at ⁇ 10 microns (infrared).
- the resonance wavelength increases but the relative strength of the resonance decreases (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.). This makes overall light scatter and absorption dependent on two size factors, the geometrical cross section, G, and the size-dependent position and relative strength of the resonance wavelength.
- the silver particle resonance in the small particle limit is at ⁇ 400nm and agrees exactly with a semiconductor diode laser wavelength (see US 6,413,786, hereby incorporated by reference in its entirety). Unfortunately, with today's technology this laser is expensive and not reliable. Gold can also be used to make optically resonant particles (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.) and gold has advantages over silver in that the attachment of binding molecules to gold is very straightforward. The gold resonance at ⁇ 530nm agrees exactly with another laser that is also expensive and unreliable. But the gold resonance wavelength can be tuned upward toward 635nm where an inexpensive, durable, and very reliable semiconductor laser emits light.
- the upward tuning of the gold resonance toward 635nm works only over a • defined particle size range.
- This size range is determined as follows.
- the resonance maximum shifts to longer wavelengths as the particle size increases. This increases light scatter at longer wavelengths. Light scatter increases as the geometric cross section of the particle increases. However as the resonance maximum shifts to longer wavelengths, the strength of the maximum decreases, which tends to decrease light scatter. These competing factors can produce an optimum particle size. This effect is illustrated in Figure 2.
- Fig 3 Gold sols with relatively monodisperse diameters were analyzed in a spectrophotometer. Relative, light absorption intensity at 635nm was plotted versus gold particle size for each sol. The optimum size is seen to be near 60nm or slightly greater where there is a peak for light absorption intensity. Where there are peaks in absorption, there will be peaks for light scatter with ORP's. This is demonstrated in the next example where light scatter from cells was recorded in a multi-angle flow cytometer using particles sizes in the vicinity of the peak shown in Figure 3.
- Fig 4 Three sizes of gold particle were used to label cells and were analyzed by a light- scatter flow cytometer with a semiconductor diode laser at a wavelength of 635nm (Fig 4).
- the particle sizes were 40nm, 80nm, and lOOnm.
- 40nm particles the labeling of lymphocytes was undetectable (Fig 5 a).
- 80nm particles the gold labeled lymphocytes were clearly detectable as a second dot cluster shifted to the right (Fig. 5b).
- lOOnm particles the second cluster was clearly detectable, but the shift to the right was less than with 80nm particles (Fig. 5 c). This is in agreement with the graph of
- Example of Resonance Optimizing the Resonance Wavelength Downward hi this example, 50nm silver particles were suspended in water and shown to resonate at 442nm (Fig 6). A semiconductor diode laser exists at 400nm. Decreasing the particle size will shift the silver resonance downward and will increase the strength of the resonance. Both of these effects will increase light scatter. The geometric cross section will decrease, which will tend to lower light scatter. Using the same experimental technique that was outlined for determining the optimum increase in gold particle size, one can experimentally determine the optimal particle size decrease to produce maximum light scatter from a 400nm diode laser with silver.
- Optically Resonant Materials Capable of Optimization
- metallic elements gold and silver in the visible spectrum
- compounds silicon dioxide in the near infrared spectrum
- semiconductors silicon carbide in the middle infrared spectrum
- the particle could be a metal colloidal sol
- the selectively binding molecule could be an antibody
- the characteristic receptor could be an antigen to that antibody.
- centrifugation requires a high skill level to perform and adds additional equipment expense to the cost of manufacturing a system to perform the assay that is part of the subject matter of this invention.
- Manual vortex-mixing is highly dependent on operator skill, and is highly variable in end result from operator to operator. It is carried out by holding a test tube containing the reaction mixture in a loose finger grip near the top, and pressing the bottom of the tube onto a pressure-activated rotating eccentric wheel. The bottom of the test tub describes a circular arc while the top remains relatively stationary. The angle at which the operator holds the tube, the pressure exerted on the wheel, and number of total revolutions, all determine the rate of reaction.
- the following example illustrates the application of the present invention in overcoming the shortcomings of these prior art methods, while enhancing the rate of particle binding to the target cells.
- Receptors are finite in size and are generally spaced randomly over the surface of the cell, which means that not all collisions between the particle and the cell will result in binding.
- the kinetics of binding under these circumstances has been studied by Berg and Purcell (H.C. Berg and E.M.Purcell, "The Physics of Chemoreception", Biophysical Journal, 20, 193 (1977)), and the following equations can be used to predict the rate at which particles would bind to the cell surface.
- J J max [Ns/(Ns + ⁇ a)]
- the particle concentration, C p; is 8E11/ cm 3 (30 Optical Density Units at 555nm). With this concentration, and according to the above equation, J ⁇ 50/sec. Therefore, the time required to cover all the approximate 50,000 CD4 receptor sites on a human T-lymphocyte should be about 15 minutes.
- Increasing the reaction temperature from 20C to 37C increases the particle diffusion coefficient (Physics with Illustrative Examples from Medicine and Biology (Second Edition), George B. Benedek and Felix M.H. Villars, ATP Press, pl23 Statistical Physics).
- the particle diffusion coefficient is a linear function of the Kelvin temperature, therefore increasing the reaction temperature from 20C to 37C is only a 5% increase on the Kelvin scale (293K to 31 OK).
- the predicted reaction time to saturate the CD4 sites on a human T-lymphocyte remains at approximately 15 minutes. While these predicted times are useful for a rapid diagnostic test, they proved to be grossly false when evaluated in practice.
- Hexadimethrine bromide is a polycationic surfactant that with known ability to coat negatively charged surfaces and reduce or neutralize negative charge.
- Tien et al Joe Tien, Andreas Terfort, and George M. Whitesides, Microfabrication Through Electrostatic Self-Assembly , Langmuir 1997, 13, 5349-5355 ) have demonstrated that when PO 3 H " -termination, or CO 2 " -termination, or polyvinylsulfonate-coating was used to create negatively charged gold particles, immersion in hexadimethrine bromide solutions of 20mM for 10 to 30 minutes reduced the negative charge.
- hexadimethrine bromide has been used to reduce surface charge
- red cell blood grouping assay application for blood transfusion
- free antibodies against a specific red cell blood group surface antigen are added to a suspension of red cells.
- the antibodies bind to the red cells, but being negatively charged the red cells repel and the antibody is not able to make a bridge between two red cells.
- the cell charge is reduced, and the antibody can bridge the distance between two cells. This results in the agglutination of red cells, which is an end point that is easily detectable by the unaided eye.
- Agglutination in the presence of hexadimethrine bromide provides a rapid blood grouping assay.
- Each ORP acts as a point source of scattered light. Since the incident light is coherent, the phase of the excitation at each point source is fixed by the position of the ORP. Under these conditions, the reradiated coherent light is additive in certain directions and subtractive in others.
- ORP spacing and scattering angle pairs can be calculated once the spacing between ORP's is known.
- CD4 subset of lymphocytes There are -50,000 CD4 binding sites on a CD4 lymphocyte.
- next nearest neighbor pairs (2 ⁇ 0 ) is also too small, but the next-next nearest neighbors ( 3 ⁇ 0 ) are spaced at 0.24 ⁇ and this gives 180 degree light scatter.
- the table below shows that most of the coherently scattering ORP's scatter light at very wide angles.
- Figure 8 shows four distinct clusters in a plot of FSH versus FSL. Unlysed red cells and platelets lie in the lower left most cluster. Lymphocytes lie in the left-hand cluster above the unlysed red cells and platelets, monocytes are in the cluster to the right of the lymphocytes, and granulocytes are in the upper cluster.
- Figure 8 a shows the cluster positions after incubation with 80nm colloidal gold conjugated with a non-binding goat anti-mouse antibody.
- Figure 8b was obtained by incubating 80nm colloidal gold conjugated to anti-CD4 monoclonal antibody. It shows that the lymphocyte cluster showed no change in either FSL or FSH as a result of ORP binding to lymphocytes.
- TOF time of flight
- FIG 10 shows a plot of RAS versus EXT.
- Granulocytes are in the cluster to the upper right, monocytes are in the cluster to the left of the granulocytes, and lymphocytes are in one cluster below the monocytes and granulocytes in the absence of colloidal gold binding (Figure 10a).
- Figure 10b shows two lymphocyte clusters instead of one as shown in Figure 10b.
- the CD4 positive lymphocytes that are labeled with colloidal gold are in the right hand lymphocyte cluster. This is in agreement with the hypothesis that RAS will be affected by gold particles bound to the lymphocyte cell surface, and that CD4 positive lymphocytes can be enumerated.
- This example illustrates one aspect of the current invention which is to combine information from multi-angle light scatter from cells themselves with information from multi-angle light scatter from colloidal gold particles bound to specific cell surface markers in order to identify and enumerate specific cell types.
- Boolean gating of lymphocytes is demonstrated.
- the blood sample used in this case contained granulocytes with abnormal EXT values. These abnormal granulocytes appear in the same region on a plot of EXT versus RAS as do the CD4 positive lymphocytes. Such overlap would invalidate the CD4 count.
- This serious error is avoided by first using the Boolean gate that, "only those cells that lie within the lymphocyte cluster for FSH versus FSL (or EXT)" are admitted by the gate, and then only cells passing through that gate are used in the EXT versus RAS plot.
- FIG. 12 An example is shown in Figure 12. Abnormal granulocytes interfered with un- gated CD4 lymphocyte counting, and produced an incorrectly elevated CD4 count. When the Boolean gate was applied, the interfering granulocytes were eliminated, and the correct CD4 count was obtained. Avoiding such interference is extremely important with HIV positive patients whose actual CD4 lymphocyte count is low and is near the level where decisions to start therapy must be made before the CD4 count drops to the point where opportunistic infections endanger the life of the patient.
- This gating technique can be extended to other cell groups. For example if monocytes are labeled with ORP's they shift onto the very dense granulocyte cluster in EXT-RAS space. The small number of shifted monocytes would be very difficult to resolve against the high granulocyte background. By gating on monocytes in FSL-FSH space and viewing the shifted monocytes in EXT-RAS space, the granulocytes are eliminated from the background. The same gating techniques can be applied to the identification of other lymphocyte subsets such as CD8 positive or CD3 positive lymphocytes, or natural killer cells.
- the class of materials suitable for the present invention are those for which the real part n of the refractive index approaches zero and the imaginary part of the refractive index, k approaches ⁇ 2 at one or more wavelengths, X R .
- Such wavelengths are termed “resonant wavelengths” or “resonances” for the purposes of this invention.
- resonant wavelengths or “resonances” for the purposes of this invention.
- the colloidal material preferably contains particles including metals and metal compounds, such as metal oxides, metal hydroxides and metal salts.
- metals include gold, platinum, silver and copper. Gold is highly preferred.
- Methods of production of colloidal gold of the desired range of particle diameters, and methods for coating metal particles with proteins, are described generally in European patent application 426,300, Roth, J., "The Colloidal Gold Marker System for Light and Electron Microscopy Cytochemistry", in Bullock, G. R. et al., Techniques in Jmmunocytochemistry 2:217 (1983), in Horisberger, M., SEM 11:9 (1981), in Weiser, H. B., Inorganic Colloid Chemistry, J. Wiley, N.Y. 1931, p. 1, in Leuvering, J. H. W., U.S. Pat. No. 4,313,734, and in Frens, G., Nature, Physical Science, 241 :20 (1973), all of which are incorporated by reference.
- the ORP's used in the methods of the present invention are conjugated to cell specific binding compounds.
- Suitable cell specific binding compounds for use in the present invention include antibodies.
- antibody encompasses monoclonal antibodies, polyclonal antibodies, multispecif ⁇ c antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity or specificity.
- Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments.
- Antibodies raised against cell specific surface molecules are produced by immunizing a host animal with a cell surface receptor protein or an antigenic fragment thereof.
- Suitable host animals for injection of the protein immunogen include, but are not limited to, rabbits, mice, rats, goats, and guinea pigs.
- Various adjuvants may be used to increase the immunological response of the immunogen or antigen (i.e., the cell surface receptor protein or peptide) in the host animal.
- the adjuvant used depends, at least in part, on the host species. For example, guinea pig albumin is commonly used as a carrier for immunizations in guinea pigs.
- Such animals produce heterogeneous populations of antibody molecules, which are referred to as polyclonal antibodies and which may be derived from the sera of the immunized animals. Such sera may be used directly, or the specific antibodies desired can be purified from the sera, using methods well known to those of skill in the art.
- Antibodies are also prepared using an oligopeptide having a sequence which is identical to a portion of the amino acid sequence of a cell surface receptor protein isoform.
- the oligopeptide has an amino acid sequence of at least five amino acids, and more preferably, at least 10 amino acids that are identical to a portion of the amino acid sequence of a cell surface receptor protein.
- Such peptides are conventionally fused with those of another protein such as keyhole limpet hemocyanin and antibody is produced against the chimeric molecule.
- Such peptides can be determined using software programs, for example the MacVector program, to determine hydrophilicity and hydrophobicity and ascertain regions of the protein that are likely to be present at the surface of the molecule.
- monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site, also called epitope. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method, first described by Kohler and Milstein (Nature 256:495-497, 1975), in which case the hybridoma cell lines that are obtained secrete the monoclonal antibodies during growth.
- hybridomas that secrete monoclonal antibodies are made by injecting mice with the desired antigen.
- the antigens frequently are peptide antigens which are chosen using similar procedures as described above for selection of peptide antigens for making polyclonal antibodies.
- spleen cells are taken from the immunized mice and are fused to myeloma cells. Clones of fusion cells are then obtained and are screened for production of anti- cell surface receptor antibodies.
- immunoassays may be used for screening to identify antibodies having the desired specificity. These include protocols which involve competitive binding or immunoradiometric assays and typically involve the measurement of complex formation between the respective cell surface receptor protein and the antibody.
- the hybridoma cell lines may be grown in cell culture and culture medium containing the monoclonal antibodies collected.
- the hybridoma cell lines maybe injected into, and grown within, the peritoneal cavity of live animals, preferably mice.
- the monoclonal antibodies are secreted.
- This peritoneal fluid, called "ascites,” is collected using a syringe to obtain the monoclonal antibodies.
- Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, Iga, IgD and any class thereof
- Antibody preparations may be isolated or purified.
- An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
- the antibody may be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS- PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
- Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step
- Antibodies immunospecific for cell surface receptor are useful for identifying cells or tissues in accordance with the methods of the present invention.
- the identification and quantification of specific cells and tissues are useful in numerous diagnostic/prognostic methods for identifying or monitoring equally numerous diseases and disorders, including those related immunology, oncology, cardiology and neurology.
- ORP's used in the methods of the present invention are conjugated to cell specific binding compounds.
- Factors important in preparing ORP/cell specific binding compound conjugates include ORP composition and concentration, pH, ionic strength, as well as the composition and concentration of the cell specific binding compound. Optimization of these factors is required to produce each particular ORP/cell specific binding compound conjugate and optimization is readily accomplished by one skilled in the art.
- ORP's can, be coated with the binding protein streptavidin (MW
- Cationic surfactants are generally positively charged quaternary ammonium compounds. In the context of the present invention, they act to accelerate the reaction between ORP's and and cell surface receptors significantly by neutralizing the negative Coulombic forces that slow the reaction, thereby avoiding the currently necessary step(s) of centrfugation or vortexing.
- a preferred cationic surfactant useful in the methods of the present invention is hexadimethrine bromide.
- cationic surfactants that are effective for use in the present invention include, but are not limited to, decamethonium bromide, polydiallyldimethylammonium chloride, hexadecyltrimethylammonium bromide, tetramethyl ammonium, tetrapropyl ammonium, tetrabuytl ammonium, cetyltrimethyl ammonium and myristylmethyl ammonium, (generally see, Cationic Surfactants: Physical Chemistry; Surfactant Science Series, Vol. 37; Editors: Rubingh,D.N and Holland, P.M.; Dekker Publishing; 1991; ISBN 0824783573).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
This invention relates to the field of biological assays where cells can be classified and enumerated using flow cytometry optical instrumentation. The invention combines information from multi-angle, light scatter from the cell itself and multi-angle light scatter from small, optically resonant particles that are selectively bound to surface molecules on the cell to carry out classification and enumeration. This light scatter method enables an instrumentation system that is simple to use, inexpensive to build, and mechanically robust; making it suitable for use in remote clinical environments.
Description
ENHANCED CELLULAR ASSAY METHOD FOR USE IN FLOW CYTOMETRY OR SIMILAR INSTRUMENTS USING OPTICALLY RESONANT PARTICLES
Priority The present application claims priority to U.S. Provisional Application No.
60/473,732, filed May 27, 2003.
Field of the Invention:
This invention relates to the field of biological assays where cells can be classified and quantified using flow cytometry and other optical instrumentation.
Background:
Selective binding of polystyrene particles, gold particles, silver particles, as well as polystyrene particles coupled to gold and silver particles have been used to identify cell types in a laser flow cytometer by light scatter rather than by fluorescence (Bohmer, King. Journal of Immunologic Methods, "Immuno-Gold Labeling for Flow Cytometric Analysis. 74(1984)49-57; Bohmer, King. Cytometry. "Flow Cytometric Analysis of Immunogold Cell Surface Label. 5(1984)543-546; Festin, Bjorklund. Journal of Immunological Methods, "Detection of Triple Antibody-binding Lymphocytes in a Standard Laser Flow Cytometry using Colloidal Gold, Fluorescein and Phycoerythrin as Labels". 101(1978) 23-28). While a light-scatter laser flow cytometer is simpler, more durable, and significantly less expensive to manufacture than a fluorescence flow cytometer, these prior art light scatter assay methods need several complex user steps or expensive manufacturing steps to enhance the light scatter signal, and create a detectable signal over background light scatter from the cells themselves.
The need for multiple steps by a skilled user and/or the high cost of manufacture, prevents these prior art particle binding assays from being used in resource-poor environments where highly trained laboratory technicians are not widely available, and
health care is poorly financed. Within the industrialized nations, eliminating the need for a highly trained laboratory technicians and reduced manufacturing cost is desired for health care cost containment.
Summary of the Invention:
The present invention uses the combination of the inherent, multi-angle light scatter from cells and the multi-angle light scatter from small particles that are selectively bound to surface molecules that are characteristic of the cell to identify and quantify cells in liquid suspension. The present invention uses methods of signal enhancement from light scatter particle labels that make the assay simple to use and inexpensive to manufacture, and novel flow cytometry apparatus that combines the particle label multi- angle light scatter signal with the inherent light scatter signal from the cell to positively identify and quantify the cell type.
The invention uses particle materials that exhibit abnormally high light scattering efficiencies at certain "resonance wavelengths" (Optically Resonant Particles, ORP's) (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.). This resonance can greatly enhance the signal strength and enable a more sensitive cell identification assay. Unfortunately, these resonance wavelengths and available laser wavelengths are not always the same. The invention teaches a method of using ORP size to "tune" the resonance wavelength and strength of the resonance simultaneously to an optimum relative to the laser wavelength.
As such, the present invention relates to a method for the detection of an Optically Resonant Particle (ORP) by light scattering comprising the simultaneous optimization of the resonance wavelength and strength of resonance of the ORP to the laser excitation wavelength, whereby the resonance wavelength can be modified by increasing or decreasing the size of the ORP.
Second, the present invention teaches a method of chemically accelerating the particle binding reaction to produce a detectable signal on a light scatter flow cytometer
without centrifuging or "vortex" mixing the sample and reagent. Surface charge must be maintained in order to store a colloidal suspension for later use, but when this particle surface charge and the cell surface charge are of the same sign, then mechanical means such as centrifugation or manual "vortex" mixing have been used to force the particles and cells into contact. (Joe Tien, Andreas Terfort, and George M. Whitesides, Microfabrication Through Electrostatic Self- Assembly , Langmuir 1997, 13, 5349-5355) The method of the present invention relies on changing the surface charge characteristics of the particle and the cells in the sample by chemical means that are low cost and do not rely on the manual skill of the operator.
As such, the present invention relates to a method of decreasing the Coulombic forces between cell surface receptors and ORP's comprising the treatment of a sample containing cell surface receptors and ORP's with a cationic surfactant, wherein the cationic surfactant can be selected from the group consisting of decamethonium bromide, polydiallyldimemylammonium chloride and hexadecyltrimethylammonium bromide.
Third, the present invention teaches multi-angle light scatter flow cytometry apparatus that combines light scatter from the cell itself with light scatter signal from the particles that are bound to the cell surface to make Boolean logic judgements as to the biological identity of cells, and count only those that satisfy certain logical conditions
(see U.S. 4,284,412). Light scatter angles not sensitive to ORP's but otherwise sensitive to the inherent light scatter properties of cells are used to gate a flow cytometer on certain classes cells and light scatter angles sensitive to ORP's are used to identify and quantify sub-classes of said classes of cells.
As such, the present invention relates to a method for the identification and quantification of cells using a flow cytometer that employs the combination of inherent, multi-angle light scatter from cells and multi-angle light scatter from Optically Resonant Particles (ORP's) conjugated to cell specific binding compounds that selectively bind to surface structures characteristic of specific cells.
As a general example of the present invention, where CD4 positive, human T- lymphocytes are identified and quantified in a whole blood sample. The light scatter signal from colloidal gold particles is optimized for maximum strength by size selection according to the laser wavelength used for detection. They are conjugated with anti-CD4 monoclonal antibodies and reacted with human whole blood using a reaction buffer that neutralizes particle surface charge and accelerates the reaction without the need for centrifugation or manual "vortex" mixing. Finally, a multi-angle light scatter apparatus is described and used to distinguish and count lymphocytes bearing the CD4 surface marker from monocytes that also bear the CD4 surface marker, or interfering granulocytes with similar light scatter signals, thus making the method and apparatus valuable for monitoring the concentration of CD4 positive T-lymphocytes in HlV-infected patients. This is a key diagnostic parameter in AIDS therapy management. Other examples are offered for the detection of other cell subsets.
The present invention uses a simple assay that is inexpensive to automate and inexpensive to manufacture. The invention uses reagents that have an inherently low manufacturing cost while providing a strong signal that can be analyzed automatically without the need for a skilled flow cytometry operator exercising human judgment to separate the signal from background. Applications for the present invention include AIDS antiretroviral therapy monitoring in resource poor parts of the world and in remote public health centers in the industrialized world.
Brief Description of the Figures:
Figure 1 contains diagrammatic representations of optical resonance for 40nm gold particles and 40nm silver particles in colloidal suspension.
Figure 2 is a diagrammatic representation of tuning an optical resonance to a longer wavelength by increasing particle size.
Figure 3 is a bar graph representation of light absorption from gold particles as a function of particle size.
Figure 4 is a schematic illustration of a multi-angle light scatter flow cytometer; including sensors for extinction (EXT), low angle forward scatter (FSL), high angle forward scatter (FSH) and right angle scatter (RAS). Figure 5 represents the results of light scatter flow cytometric analysis with a semiconductor diode laser at a wavelength of 635nm for gold particles with sizes of 40nm (a), 80nm (b) and lOOnm (c).
Figure 6 is a diagrammatic representation of an absorption spectrum of 50 ran silver colloids with resonance peak at 423nm.
Figure 7 are diagrammatic representations of the comparative resolution of CD4+ lymphocyte clusters, (a) after 3 hour incubation at 37 degrees centigrade without accelerant, and (b) after a 5 minute incubation at 37 degrees centigrade with 0.1% hexadimethrine bromide.
Figure 8 are diagrammatic representations of comparative positions of lymphocyte clusters (a) using FSH versus FSL with a nonbonding control reaction and (b) using FSH versus FSL when anti CD4 conjugated colloidal gold binds to the lymphocyte surface.
Figure 9 are diagrammatic representations of comparative positions of lymphocyte clusters (a) using FSH versus TOL with a nonbonding control reaction with colloidal gold and (b) using FSH versus TOL when anti CD4 conjugated colloidal gold binds to the lymphocyte surface.
FigurelO are diagrammatic representations of plots of RAS versus EXT; wherein (a) granulocytes are in the cluster to the upper right, monocytes are in the cluster to the left of the granulocytes, and lymphocytes are in one cluster below the monocytes and granulocytes in the absence of colloidal gold binding; and (b) in the presence of anti-CD4 conjugated colloidal gold binding there are two lymphocyte clusters instead of one, the
CD4 positive lymphocytes that are labeled with colloidal gold are in the right hand lymphocyte cluster.
Figure 11 is a diagrammatic representation of a plot of RAS versus EXT; wherein abnormal granulocyte cluster interferes with non-gated CD4 positive lymphocyte counting.
Figure 12 are diagrammatic representations of plots illustrating (a) gating lymphocytes by FSH versus TOF; (b) interference between CD4 lymphocytes and abnormal granulocytes in an un-gated dot plot by RAS versus EXT; and (c) no interference using gated dot plot by RAS versus EXT.
Detailed Description of the Invention:
This invention relates to the field of biological assays where cells can be classified and enumerated using flow cytometry optical instrumentation. The invention combines information from multi-angle, light scatter from the cell itself and multi-angle light scatter from small, optically resonant particles that are selectively bound to surface molecules on the cell to carry out classification and enumeration. This light scatter method enables an instrumentation system that is simple to use, inexpensive to build, and mechanically robust; making it suitable for use in remote clinical environments.
A. Optical Resonance and Methods of Optimizing the Detection ORP's:
The present invention uses small particles that are chemically pre-conjugated to molecules, such as antibodies, that bind selectively to sites on the surface of cells. The characteristic light scatter pattern of the cell is modified by the bound particles and this modification can be detected by the use of a microscope, a flow cytometer, a spectrophotometer or other similar optical instrumentation. Flow cytometry is the preferred embodiment of the present invention.
Optically small particles are particles that are smaller than the wavelength of the incident light. When the refractive index of the particles has both real and imaginary parts, N = (n+ik), the particle not only scatters light, but it also absorbs light.
The amount of light scattered or absorbed by a particle is, in part, proportional to its geometric cross-sectional area, G. For a spherical particle, G = πa , where a is the particle radius. In addition to this geometrical factor, the amount of light scattered or absorbed is a function of wavelength. Most particles have real and imaginary parts of the refractive index that are not in themselves strong functions of wavelength. Under these common conditions, the wavelength dependence for scattering and absorption is simple. Scattering is proportional to λ"4 and absorption is proportional to λ _1 .
Some small particles have real and imaginary parts of the refractive index, N = (n+ik), that are strong functions of wavelength, λ. Under certain conditions, the scattering efficiency and absorption efficiency can depart significantly from the simple wavelength laws of λ"4 and λ _1, and become abnormally high and reach a local maximum at a "resonance wavelength" λR. This occurs when the real part, n(λ), approaches 0, and the imaginary part, k(λ), approaches 2, at a wavelength XR (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.). Such particles are called ORP's or Optically Resonant Particles (Fig 1).
The resonance wavelength and relative strength of the resonance are also functions of the size of the particle. As the particle size approaches zero the resonance wavelength approaches a minimum value and a maximum relative strength that is dependent on the particle material. Examples of resonant particle materials and their associated minimum resonance wavelengths are aluminum at ~200nm (ultraviolet), silver at ~400nm (visible), gold at ~530nm (visible), and silicon carbide at ~10 microns (infrared). As the particle size increases, the resonance wavelength increases but the relative strength of the resonance decreases (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.). This makes overall
light scatter and absorption dependent on two size factors, the geometrical cross section, G, and the size-dependent position and relative strength of the resonance wavelength.
The following is an example of how these factors are used in the present invention to optimize light scatter for a particular laser excitation. The silver particle resonance in the small particle limit is at ~400nm and agrees exactly with a semiconductor diode laser wavelength (see US 6,413,786, hereby incorporated by reference in its entirety). Unfortunately, with today's technology this laser is expensive and not reliable. Gold can also be used to make optically resonant particles (Bohren and Huffman, Absorption and Scattering of Light by Small Particles, Wiley Interscience, 1983.) and gold has advantages over silver in that the attachment of binding molecules to gold is very straightforward. The gold resonance at ~530nm agrees exactly with another laser that is also expensive and unreliable. But the gold resonance wavelength can be tuned upward toward 635nm where an inexpensive, durable, and very reliable semiconductor laser emits light.
The upward tuning of the gold resonance toward 635nm works only over a • defined particle size range. This size range is determined as follows. The resonance maximum shifts to longer wavelengths as the particle size increases. This increases light scatter at longer wavelengths. Light scatter increases as the geometric cross section of the particle increases. However as the resonance maximum shifts to longer wavelengths, the strength of the maximum decreases, which tends to decrease light scatter. These competing factors can produce an optimum particle size. This effect is illustrated in Figure 2.
The optimum size is demonstrated in Fig 3. Gold sols with relatively monodisperse diameters were analyzed in a spectrophotometer. Relative, light absorption intensity at 635nm was plotted versus gold particle size for each sol. The optimum size is seen to be near 60nm or slightly greater where there is a peak for light absorption intensity. Where there are peaks in absorption, there will be peaks for light scatter with ORP's. This is demonstrated in the next example where light scatter from cells was
recorded in a multi-angle flow cytometer using particles sizes in the vicinity of the peak shown in Figure 3.
Three sizes of gold particle were used to label cells and were analyzed by a light- scatter flow cytometer with a semiconductor diode laser at a wavelength of 635nm (Fig 4). The particle sizes were 40nm, 80nm, and lOOnm. With 40nm particles the labeling of lymphocytes was undetectable (Fig 5 a). With 80nm particles, the gold labeled lymphocytes were clearly detectable as a second dot cluster shifted to the right (Fig. 5b). With lOOnm particles, the second cluster was clearly detectable, but the shift to the right was less than with 80nm particles (Fig. 5 c). This is in agreement with the graph of
Figure 3, suggesting that optimal light scatter occurs for a particle size between 40nm and lOOnm.
Example of Resonance Optimizing the Resonance Wavelength Downward: hi this example, 50nm silver particles were suspended in water and shown to resonate at 442nm (Fig 6). A semiconductor diode laser exists at 400nm. Decreasing the particle size will shift the silver resonance downward and will increase the strength of the resonance. Both of these effects will increase light scatter. The geometric cross section will decrease, which will tend to lower light scatter. Using the same experimental technique that was outlined for determining the optimum increase in gold particle size, one can experimentally determine the optimal particle size decrease to produce maximum light scatter from a 400nm diode laser with silver.
Other Examples of Optically Resonant Materials Capable of Optimization These techniques can be extended to any optically resonant particle regardless of its composition. For example, the same principles apply to metallic elements (gold and silver in the visible spectrum), compounds (silicon dioxide in the near infrared spectrum), and semiconductors (silicon carbide in the middle infrared spectrum).
Preference for Light Scatter Over Fluorescence
Light scatter labels are to be preferred over fluorescent labels for reasons of instrumentation stability, cost and ease of use. Fluorescent light in flow cytometers must be collected and, most importantly, collimated so as to strike the surface of costly, multilayer dielectric filters within approximately 2 degrees of perpendicularity. If this condition is not met, then the transmission characteristics of the filter change significantly. When this happens, laser light is inadvertently transmitted to the photomultiplier sensor and fluorescence detection is rendered impossible due to high background. It is well-known in the art that maintaining optical alignment of the collimating lenses and filters in a fluorescence flow cytometer is difficult, requiring frequent field adjustment and a costly mechanical design that allows adjustment. With light scatter, filters are not needed; hence the collimating lenses can be eliminated. Under these conditions, simple silicon photodiodes can be rigidly mounted together with the flow cytometer flow cell, with no adjustment mechanism required.
B. Particle Binding Kinetics of ORP's to the Cell Surface and Methods of Overcoming Coulombic forces :
Consider a small particle in liquid suspension that moves by predominantly by Brownian motion and is smaller than a cell. Let this particle be coated with a molecule that selectively binds to characteristic receptors on the surface of a cell type. For example, the particle could be a metal colloidal sol, the selectively binding molecule could be an antibody, and the characteristic receptor could be an antigen to that antibody.
In prior art methods the rate at which antibody-coated colloidal metal particles bind to cell surface receptors was enhanced by centrifugation or manual vortex mixing (Bohmer, King. Journal of Immunologic Methods, "Immuno-Gold Labeling for Flow Cytometric Analysis. 74(1984)49-57; Bohmer, King. Cytometry, "Flow Cytometric Analysis of Immunogold Cell Surface Label. 5(1984)543-546; Festin, Bjorklund. Journal of Immunological Methods, "Detection of Triple Antibody-binding Lymphocytes in a Standard Laser Flow Cytometry using Colloidal Gold, Fluorescein and Phycoerythrin as Labels". 101(1978) 23-28; Olvai Siiman, Kristie Gordon, Alexander Burshteyn, John A. Maples, and James K. Whitesell. Cytometry, "Immunophenotyping Using Gold or
Silver Nanoparticle-Poiystyrene Bead Conjugates With Multiple Light Scatter". 41 :298- 307 (2000)). Both methods have similar physical principles at their foundation. Centrifugation creates a relative motion between the particle sol and the cell as the cell is driven toward the bottom of the centrifuge tube by the "g" force. The cell sweeps out a path in the sol, and more particles per unit time are able to collide by diffusion with the surface of the cell. Manual vortex mixing creates fluid shear within the reaction liquid. Particles that randomly cross shear lines by Brownian motion collide with cells moving at different collective, unidirectional velocities and hence more particles per unit time are able to collide by diffusion with the surface of the cell.
Neither centrifugation nor manual vortex-mixing are desirable methods for reaction rate enhancement. Centrifugation requires a high skill level to perform and adds additional equipment expense to the cost of manufacturing a system to perform the assay that is part of the subject matter of this invention. Manual vortex-mixing is highly dependent on operator skill, and is highly variable in end result from operator to operator. It is carried out by holding a test tube containing the reaction mixture in a loose finger grip near the top, and pressing the bottom of the tube onto a pressure-activated rotating eccentric wheel. The bottom of the test tub describes a circular arc while the top remains relatively stationary. The angle at which the operator holds the tube, the pressure exerted on the wheel, and number of total revolutions, all determine the rate of reaction. The following example illustrates the application of the present invention in overcoming the shortcomings of these prior art methods, while enhancing the rate of particle binding to the target cells.
Receptors are finite in size and are generally spaced randomly over the surface of the cell, which means that not all collisions between the particle and the cell will result in binding. The kinetics of binding under these circumstances has been studied by Berg and Purcell (H.C. Berg and E.M.Purcell, "The Physics of Chemoreception", Biophysical Journal, 20, 193 (1977)), and the following equations can be used to predict the rate at which particles would bind to the cell surface.
J = Jmax [Ns/(Ns + πa)]
Jmax = 4πaDcp
J = Rate of particle binding to a cell (number per second)
Jma = Maximum rate of particle binding N = Number of receptors on the cell s = Radius of the receptor (cm) a = Cell radius (cm) , D = Diffusion coefficient for particle in water (cm2 /sec)
Cp = Concentration of particles (number per cm3)
According to this equation, if one wishes to increase the rate of binding of particles to cells of a specific type, then one can increase the particle concentration, Cp , or the diffusion coefficient of the particle, D.
As an example, consider gold sols with a particle diameter of 80nm (.08μ or 8E- 6cm). The diffusion coefficient at temperature of 20C for a particle of this size can be calculated and is 5E-8 cm2/sec. A typical protein receptor has a radius of about 50 Angstrom units or 5E-7 cm. A cell such as a lymphocyte has a radius of 5 μ or 5E-4 cm. There are ~ 50,000 CD4 receptors on the surface of a lymphocyte. Combining these values in the above equation one can calculate that:
J = (7E-11 cm /sec) Cp .
With an undiluted stock solution of 80nm gold sol, the particle concentration, Cp; is 8E11/ cm3 (30 Optical Density Units at 555nm). With this concentration, and according to the above equation, J ~ 50/sec. Therefore, the time required to cover all the approximate 50,000 CD4 receptor sites on a human T-lymphocyte should be about 15 minutes.
Increasing the reaction temperature from 20C to 37C increases the particle diffusion coefficient (Physics with Illustrative Examples from Medicine and Biology (Second Edition), George B. Benedek and Felix M.H. Villars, ATP Press, pl23 Statistical Physics). The particle diffusion coefficient is a linear function of the Kelvin temperature, therefore increasing the reaction temperature from 20C to 37C is only a 5% increase on the Kelvin scale (293K to 31 OK). Thus the predicted reaction time to saturate the CD4 sites on a human T-lymphocyte remains at approximately 15 minutes. While these predicted times are useful for a rapid diagnostic test, they proved to be grossly false when evaluated in practice.
In practice, the time to saturate the sites on a human T-lymphocyte was found to be in excess of 3 hours which is in marked disagreement with the predictions of the Berg and Purcell model. The source of this significant discrepancy lies in the fact that both the human T-lymphocyte and the gold particle have like surface charges. Both are negatively charged, and hence low energy collisions are prevented by Coulombic forces of repulsion.
We have found that the addition of hexadimethrine bromide to the reaction solution accelerates the reaction significantly by neutralizing the Coulombic forces that slow the reaction.
When anti-CD4 antibody (Serotech, Inc.) was coated to 65nm colloidal gold particles and reacted with whole blood at 37C, a distinct flow cytometry cluster of CD4 positive cells was created with multi-angle light scatter detection by EXT and RAS after an incubation time of 3 hours, and these could be accurately enumerated (Fig 7a). When hexadimethrine bromide was included in the reaction solution at a concentration of 0.05% to 1.0% by volume, the time to create an equivalently distinct cluster of CD4 positive cells was reduced to approximately 4 minutes (Fig 7b). No centrifugation or vortex-mixing were employed, thus the assay cost is contained and subjectivity is removed. This accelerated reaction is important for the ability to report patient results in settings where rapid medical action is required. These settings include remote regions
where patients cannot readily communicate with the clinic if results are not ready before the patient must start the return journey to their home.
Hexadimethrine bromide is a polycationic surfactant that with known ability to coat negatively charged surfaces and reduce or neutralize negative charge. Tien et al (Joe Tien, Andreas Terfort, and George M. Whitesides, Microfabrication Through Electrostatic Self-Assembly , Langmuir 1997, 13, 5349-5355 ) have demonstrated that when PO3H" -termination, or CO2 " -termination, or polyvinylsulfonate-coating was used to create negatively charged gold particles, immersion in hexadimethrine bromide solutions of 20mM for 10 to 30 minutes reduced the negative charge.
The interior of a colloidal gold particle is electrically neutral, but the surface is negatively charged since the particles are "grown" chemically from gold chloride solutions. Un-reacted gold chloride resides on the particle surface, imparting a net negative charge to the particle. While extremely important in maintaining a colloidal particle in stable suspension over long storage times, these charges cause repulsion from the negatively charged cell surface and retard the desired binding reaction.
Other applications in which hexadimethrine bromide has been used to reduce surface charge are as a coating on capillary electrophoresis tubes and in red cell blood group assays. In a red cell blood grouping assay application (for blood transfusion), free antibodies against a specific red cell blood group surface antigen are added to a suspension of red cells. The antibodies bind to the red cells, but being negatively charged the red cells repel and the antibody is not able to make a bridge between two red cells. With the addition of hexadimethrine bromide, the cell charge is reduced, and the antibody can bridge the distance between two cells. This results in the agglutination of red cells, which is an end point that is easily detectable by the unaided eye. Agglutination in the presence of hexadimethrine bromide provides a rapid blood grouping assay.
Other cationic surfactants that are effective in coating capillary tubes and therefore would be candidates for use in the present assay in the present invention are:
1. Decamethonium bromide
2. Polydiallyldimethylammonium chloride
3. Hexadecyltrimethylammonium bromide
C) Apparatus for Multi- Angle Light Scatter from Surface-Bound Colloidal Particles and Multi- Angle Light Scatter from Whole Cells to Selectively Identify and Quantify Cell Types: Each ORP acts as a point source of scattered light. Since the incident light is coherent, the phase of the excitation at each point source is fixed by the position of the ORP. Under these conditions, the reradiated coherent light is additive in certain directions and subtractive in others.
If the average spacing between randomly placed ORP' s is Λ, the incident wavelength is λ, the refractive index of the medium is n, then the angle θ between the incident beam and the direction for which most of the light scatter occurs can be derived from the light scatter theory of granular media as sin (θ/2) = λ/2nΛ (Hansen, W.P, et al, Light Scatter as an Adjunct to Cellular hnmunofluorescence in Flow Cytometric Systems, J. Clin. Immunology, vol 2 , No. 3, July Supplement, 1982.).
The smallest spacing that causes coherent addition of light is A = λ/2n and this causes scatter at 180 degrees (backscatter). Spacings that are smaller than this do not produce coherent addition of scattered light, and only result in weak omni-directional Rayleigh scattering.
One can now calculate the direction of light scatter for ORP's of different spacing on the surface of a cell. For example with λ = .635μ (a semiconductor diode laser), and n =1.3 (water), ORP spacing and scattering angle pairs can be calculated once the spacing between ORP's is known.
As an example consider the CD4 subset of lymphocytes. There are -50,000 CD4 binding sites on a CD4 lymphocyte. A CD4 lymphocyte has a diameter of ~10μ, therefore the average spacing between ORP's that are bound to CD4 receptors is about Λ0 = 0.08μ when there is 100% coverage of the receptors. This spacing is too small to give coherent light scatter. The spacing of next nearest neighbor pairs (2 Λ0) is also too small, but the next-next nearest neighbors ( 3 Λ0 ) are spaced at 0.24μ and this gives 180 degree light scatter. The table below shows that most of the coherently scattering ORP's scatter light at very wide angles.
Light scattered in the forward direction (12 degrees or less) by gold particles bound to the cell surface is very weak compared to light they scatter at right angles or backward angles. Forward scattered light may be affected only by the cell (lymphocyte in this example) itself and not by the binding of gold particles to the cell surface. On the other hand, light scattered at right angles or backward angles is affected by gold particles bound to the cell surface. Under this hypothesis, lymphocytes might be identified by forward angle light scatter, monocytes can be rejected, and this identification can be used as a Boolean "gate" to enable counting of CD4 positive lymphocytes by wide angle and backward angle light scatter. The hypothesis was verified in the example that follows.
Nearly 100% of the light scattered by a lymphocyte without ORP's on the surface is contained within a narrow cone of forward scattered light with half angle of about 5 degrees (Hansen, W.P, et al, Light Scatter as an Adjunct to Cellular Immunofluorescence in Flow Cytometric Systems, J. Clin. Immunology, vol 2 , No. 3, July Supplement, 1982.). Referring to the table above, a detector at 90 degrees to the incident beam with
an acceptance cone of approximately 45 degrees to 180 degrees would see very low background scatter from the lymphocyte itself, and might be sensitive to ORP scatter.
To show this experimentally, light scatter from a sample of human white blood cells was simultaneously analyzed on a light scatter flow cytometer after red cell lysis. The multi-angle light scatter detectors were designated as; FSL (low angle forward scatter from 0.5 degrees to 2 degrees), FSH (high angle forward scatter from 9 degrees to 12 degrees), EXT (total light blocked) and RAS (right angle scatter from 45 degrees to 135 degrees) (Figure 4).
Figure 8 shows four distinct clusters in a plot of FSH versus FSL. Unlysed red cells and platelets lie in the lower left most cluster. Lymphocytes lie in the left-hand cluster above the unlysed red cells and platelets, monocytes are in the cluster to the right of the lymphocytes, and granulocytes are in the upper cluster. Figure 8 a shows the cluster positions after incubation with 80nm colloidal gold conjugated with a non-binding goat anti-mouse antibody. Figure 8b was obtained by incubating 80nm colloidal gold conjugated to anti-CD4 monoclonal antibody. It shows that the lymphocyte cluster showed no change in either FSL or FSH as a result of ORP binding to lymphocytes. This result is in agreement with the above hypothesis that little or no change would occur in lymphocyte light scatter at FSL and FSH angles when ORP's were bound to the CD4 receptors. Similar results are obtained when a new parameter called "time of flight" (TOF) is substituted for FSL (Fig 9). TOF is used to measure the time it takes a cell to cross the laser line focus in a flow cytometer. The timing gate is initiated and terminated from the EXT signal. The use of FSH versus TOF is preferred for the practice of this invention.
Referring to Figure 10, which shows a plot of RAS versus EXT. Granulocytes are in the cluster to the upper right, monocytes are in the cluster to the left of the granulocytes, and lymphocytes are in one cluster below the monocytes and granulocytes in the absence of colloidal gold binding (Figure 10a). In the presence of anti-CD4 conjugated colloidal gold binding there are two lymphocyte clusters instead of one as
shown in Figure 10b. . The CD4 positive lymphocytes that are labeled with colloidal gold are in the right hand lymphocyte cluster. This is in agreement with the hypothesis that RAS will be affected by gold particles bound to the lymphocyte cell surface, and that CD4 positive lymphocytes can be enumerated.
This example illustrates one aspect of the current invention which is to combine information from multi-angle light scatter from cells themselves with information from multi-angle light scatter from colloidal gold particles bound to specific cell surface markers in order to identify and enumerate specific cell types.
Referring to Figure 11, the value of Boolean gating of lymphocytes is demonstrated. The blood sample used in this case contained granulocytes with abnormal EXT values. These abnormal granulocytes appear in the same region on a plot of EXT versus RAS as do the CD4 positive lymphocytes. Such overlap would invalidate the CD4 count. This serious error is avoided by first using the Boolean gate that, "only those cells that lie within the lymphocyte cluster for FSH versus FSL (or EXT)" are admitted by the gate, and then only cells passing through that gate are used in the EXT versus RAS plot.
An example is shown in Figure 12. Abnormal granulocytes interfered with un- gated CD4 lymphocyte counting, and produced an incorrectly elevated CD4 count. When the Boolean gate was applied, the interfering granulocytes were eliminated, and the correct CD4 count was obtained. Avoiding such interference is extremely important with HIV positive patients whose actual CD4 lymphocyte count is low and is near the level where decisions to start therapy must be made before the CD4 count drops to the point where opportunistic infections endanger the life of the patient.
This gating technique can be extended to other cell groups. For example if monocytes are labeled with ORP's they shift onto the very dense granulocyte cluster in EXT-RAS space. The small number of shifted monocytes would be very difficult to resolve against the high granulocyte background. By gating on monocytes in FSL-FSH
space and viewing the shifted monocytes in EXT-RAS space, the granulocytes are eliminated from the background. The same gating techniques can be applied to the identification of other lymphocyte subsets such as CD8 positive or CD3 positive lymphocytes, or natural killer cells.
D) Components Used in the Present Invention: Optically Resonant Particles (ORP's :
The class of materials suitable for the present invention are those for which the real part n of the refractive index approaches zero and the imaginary part of the refractive index, k approaches ^2 at one or more wavelengths, XR. Such wavelengths are termed "resonant wavelengths" or "resonances" for the purposes of this invention. There is a distinct extinction spectrum maximum at the resonant wavelength for single, substantially spherical, colloidal particles that are composed of material fulfilling the above requirements.
The colloidal material preferably contains particles including metals and metal compounds, such as metal oxides, metal hydroxides and metal salts. Preferred examples of metals include gold, platinum, silver and copper. Gold is highly preferred. Methods of production of colloidal gold of the desired range of particle diameters, and methods for coating metal particles with proteins, are described generally in European patent application 426,300, Roth, J., "The Colloidal Gold Marker System for Light and Electron Microscopy Cytochemistry", in Bullock, G. R. et al., Techniques in Jmmunocytochemistry 2:217 (1983), in Horisberger, M., SEM 11:9 (1981), in Weiser, H. B., Inorganic Colloid Chemistry, J. Wiley, N.Y. 1931, p. 1, in Leuvering, J. H. W., U.S. Pat. No. 4,313,734, and in Frens, G., Nature, Physical Science, 241 :20 (1973), all of which are incorporated by reference.
, The preparation of ORP's useful in the methods of the present invention are well- known to those skilled in the art, including US Patent Nos.: 6,413,786; 6,200,820; 5,939,021; 5,589,401, 5,851,777, 5,369,037, and 5,286,452 all incorporated herein by reference in their entirety.
Cell Specific Binding Compounds:
The ORP's used in the methods of the present invention are conjugated to cell specific binding compounds. Suitable cell specific binding compounds for use in the present invention include antibodies.
The term "antibody" encompasses monoclonal antibodies, polyclonal antibodies, multispecifϊc antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity or specificity. "Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments.
Antibodies raised against cell specific surface molecules, such as receptors, are produced by immunizing a host animal with a cell surface receptor protein or an antigenic fragment thereof. Suitable host animals for injection of the protein immunogen include, but are not limited to, rabbits, mice, rats, goats, and guinea pigs. Various adjuvants may be used to increase the immunological response of the immunogen or antigen (i.e., the cell surface receptor protein or peptide) in the host animal. The adjuvant used depends, at least in part, on the host species. For example, guinea pig albumin is commonly used as a carrier for immunizations in guinea pigs. Such animals produce heterogeneous populations of antibody molecules, which are referred to as polyclonal antibodies and which may be derived from the sera of the immunized animals. Such sera may be used directly, or the specific antibodies desired can be purified from the sera, using methods well known to those of skill in the art.
Antibodies are also prepared using an oligopeptide having a sequence which is identical to a portion of the amino acid sequence of a cell surface receptor protein isoform. Preferably the oligopeptide has an amino acid sequence of at least five amino acids, and more preferably, at least 10 amino acids that are identical to a portion of the amino acid sequence of a cell surface receptor protein. Such peptides are conventionally fused with those of another protein such as keyhole limpet hemocyanin and antibody is produced against the chimeric molecule. Such peptides can be determined using software
programs, for example the MacVector program, to determine hydrophilicity and hydrophobicity and ascertain regions of the protein that are likely to be present at the surface of the molecule.
The term "monoclonal antibody" as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site, also called epitope. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
The monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method, first described by Kohler and Milstein (Nature 256:495-497, 1975), in which case the hybridoma cell lines that are obtained secrete the monoclonal antibodies during growth. As is known in the art, hybridomas that secrete monoclonal antibodies are made by injecting mice with the desired antigen. The antigens frequently are peptide antigens which are chosen using similar procedures as described above for selection of peptide antigens for making polyclonal antibodies. After the antigens have been injected into the mice, spleen cells are taken from the immunized mice and are fused to myeloma cells. Clones of fusion cells are then obtained and are screened for production of anti- cell surface receptor antibodies.
Various immunoassays may be used for screening to identify antibodies having the desired specificity. These include protocols which involve competitive binding or immunoradiometric assays and typically involve the measurement of complex formation between the respective cell surface receptor protein and the antibody.
In order to grow the hybridoma cell lines and obtain the secreted antibodies, the hybridoma cell lines may be grown in cell culture and culture medium containing the
monoclonal antibodies collected. Alternatively, the hybridoma cell lines maybe injected into, and grown within, the peritoneal cavity of live animals, preferably mice. As the hybridoma cell lines grow within the peritoneal cavity of the animal, the monoclonal antibodies are secreted. This peritoneal fluid, called "ascites," is collected using a syringe to obtain the monoclonal antibodies. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, Iga, IgD and any class thereof
Antibody preparations may be isolated or purified. An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody may be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS- PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step
Antibodies immunospecific for cell surface receptor are useful for identifying cells or tissues in accordance with the methods of the present invention. The identification and quantification of specific cells and tissues are useful in numerous diagnostic/prognostic methods for identifying or monitoring equally numerous diseases and disorders, including those related immunology, oncology, cardiology and neurology.
The ORP's used in the methods of the present invention are conjugated to cell specific binding compounds. Factors important in preparing ORP/cell specific binding compound conjugates include ORP composition and concentration, pH, ionic strength, as well as the composition and concentration of the cell specific binding compound.
Optimization of these factors is required to produce each particular ORP/cell specific binding compound conjugate and optimization is readily accomplished by one skilled in the art.
Alternatively, ORP's can, be coated with the binding protein streptavidin (MW
65,000). Coating is performed by passive adsorption at room temperature. Subsequently, the streptavidin-coated ORP's are contacted with a biotin labeled cell specific binding compound, thus achieving ORP/cell specific binding compound conjugation.
Cationic Surfactants:
Cationic surfactants are generally positively charged quaternary ammonium compounds. In the context of the present invention, they act to accelerate the reaction between ORP's and and cell surface receptors significantly by neutralizing the negative Coulombic forces that slow the reaction, thereby avoiding the currently necessary step(s) of centrfugation or vortexing. A preferred cationic surfactant useful in the methods of the present invention is hexadimethrine bromide. Other cationic surfactants that are effective for use in the present invention include, but are not limited to, decamethonium bromide, polydiallyldimethylammonium chloride, hexadecyltrimethylammonium bromide, tetramethyl ammonium, tetrapropyl ammonium, tetrabuytl ammonium, cetyltrimethyl ammonium and myristylmethyl ammonium, (generally see, Cationic Surfactants: Physical Chemistry; Surfactant Science Series, Vol. 37; Editors: Rubingh,D.N and Holland, P.M.; Dekker Publishing; 1991; ISBN 0824783573).
The examples herein are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. All documents mentioned herein are incorporated by reference in their entirety.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. It will be apparent to those skilled in the art that various modifications and variations can be made in practicing the present invention without
departing from the spirit or scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.
Claims
1. A method for the identification and quantification of cells using a flow cytometer that employs the combination of inherent, multi-angle light scatter from cells and multi- angle light scatter from Optically Resonant Particles (ORP's) conjugated to cell specific binding compounds that selectively bind to surface structures characteristic of specific cells.
2. The method of claim 1 where said particles are ORP's wherein the wavelength dependent real part of the refractive index of the ORP approaches zero and the wavelength dependent imaginary part of the refractive index approaches 2 at the resonance wavelength.
3. The method of claim 1 wherein light scatter angles not sensitive to ORP's but otherwise sensitive to the inherent light scatter properties of cells are used to gate a flow cytometer on certain classes cells and light scatter angles sensitive to ORP's are used to identify and quantify sub-classes of said classes of cells.
4. The method of claim 1 wherein the ORP is selected from the group consisting of aluminum, silver, gold and silicon carbide.
5. The method of claim 1 wherein the resonance wavelength can be modified to efficiently interact with the wavelength of the light source by increasing or decreasing the size of the ORP.
6. The method of claim 1 using a light scattering angle detection range for identifying and quantifying cells labeled with ORP's comprising a computation from the equation sin (θ/2) = λ/2nΛ , wherein A is the mean spacing between ORP's on the cell surface and λ is the excitation wavelength..
7. The method of claim 1 wherein the light scatter gating method is selected from combinations from the group consisting of peak or integral values of substantially right angle scatter, back angle scatter, time-of-flight, extinction, low angle forward scatter, or high angle forward scatter.
8. The method of claim 1 wherein the light scatter gating method is the combination of peak or integral values of low angle forward scatter and high angle forward scatter.
9. The method of claim 1 wherein the light scatter gating method is the combination of peak or integral values of high angle forward scatter and time-of-flight.
10. The method of claim 1 wherein the light scatter measurements for subclass detection by cell surface bound particles are selected from the group consisting peak or integral values of substantially right angle scatter, back angle scatter, extinction, time-of- flight, low angle forward scatter, or high angle forward scatter.
11. The method of claim 1 wherein the light scatter measurements for subclass detection by cell surface bound particles consist of integral values of substantially right angle scatter and backward angle scatter combined with integral values of extinction.
12. The method of claim 1 wherein the ORP is conjugated to an antibody directed to an antigenic site on a cell surface.
13. The method of claim 12 wherein the ORP is conjugated to an antibody by streptavidin-adsorbed ORP combined with a biotin labeled antibody.
14. The method of claim 12 wherein the antibody is directed to an antigenic site of a CD cell surface receptor.
15. The method of claim 14 wherein the CD cell surface receptor is CD3.
16. The method of claim 14 wherein the CD cell surface receptor is CD4.
17. The method of claim 14 wherein the CD cell surface receptor is CD8.
18. A method of claim 1 wherein a diagnosis of ADDS is determined by the concentration of CD4 cells detected in a test sample, in which a low number of CD4 cells in the test sample is indicative of AIDS.
19. The method of claim 18 in which said low number is 350 per microliter.
20. A method of claim 7 wherein the status of a HIV-positive patient is monitored by determining the number of CD4-positive cells detected in the patient's test sample compared to the number of CD4-positive cells detected in a control sample.
21. A method of decreasing the Coulombic forces between cell surface receptors and ORP's comprising the treatment of a sample containing cell surface receptors and ORP's with a cationic surfactant.
22. A method of claim 21 wherein the cationic surfactant is selected from the group consisting of decamethonium bromide, polydiallyldimethylammonium chloride and hexadecyltrimethylammonium bromide.
23. A method of detection by light scattering comprising the simultaneous use of (a) low angle forward scatter and high angle forward scatter to gate a cell population and (b) extinction and right angle scatter to identify and quantify ORP labeled cells from said cell population.
24. A method of detection by light scattering comprising the simultaneous use of (a) low angle scatter and high angle forward scatter to gate a subset of leukocytes and (b) extinction and right angle scatter to identify and quantify ORP labeled cells from said subset of leukocytes.
25. A method of claim 24 wherein the subset of leukocytes comprises lymphocytes.
26. A method of claim 25 wherein the lymphocytes are CD4 positive.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004243881A AU2004243881B2 (en) | 2003-05-27 | 2004-05-27 | Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles |
| EP04753650A EP1629109A4 (en) | 2003-05-27 | 2004-05-27 | Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles |
| CA002526868A CA2526868A1 (en) | 2003-05-27 | 2004-05-27 | Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47373203P | 2003-05-27 | 2003-05-27 | |
| US60/473,732 | 2003-05-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004106535A2 true WO2004106535A2 (en) | 2004-12-09 |
| WO2004106535A3 WO2004106535A3 (en) | 2006-10-26 |
Family
ID=33490639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/016855 WO2004106535A2 (en) | 2003-05-27 | 2004-05-27 | Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7611849B2 (en) |
| EP (1) | EP1629109A4 (en) |
| AU (1) | AU2004243881B2 (en) |
| CA (1) | CA2526868A1 (en) |
| WO (1) | WO2004106535A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982193A2 (en) * | 2006-01-31 | 2008-10-22 | Point Care Technologies | Cell classification system |
| US20120312085A1 (en) * | 2007-09-17 | 2012-12-13 | Luminex Corporation | System, storage mediums, and methods for identifying particles in flow |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751187A2 (en) | 2004-05-28 | 2007-02-14 | Idexx Laboratories, Inc. | Canine cd20 compositions |
| US20110129864A1 (en) * | 2009-12-02 | 2011-06-02 | Idexx Laboratories, Inc. | Method for analyzing lymph node aspirate using multi-angle light scatter flow cytometer |
| US9074978B2 (en) * | 2011-07-12 | 2015-07-07 | The Regents Of The University Of California | Optical space-time coding technique in microfluidic devices |
| JP2014062822A (en) * | 2012-09-21 | 2014-04-10 | Sony Corp | Fine particle analyzer and fine particle analyzing method |
| WO2015164123A1 (en) | 2014-04-21 | 2015-10-29 | Becton, Dickinson And Company | Slider tape sealing cartridge for adjustably sealing a flow cytometer sample manipulation chamber |
| CN107209179B (en) * | 2014-12-16 | 2019-12-20 | 积水医疗株式会社 | Test strip for immunochromatography for detecting object in sample containing red blood cells, and immunochromatography using same |
| US10571400B2 (en) | 2015-03-11 | 2020-02-25 | The General Hospital Corporation | Plasmonic nanoparticle immunoassay method |
| US10203271B1 (en) * | 2015-07-06 | 2019-02-12 | Malvern Panalytical Limited | Particle interaction characterization using overlapping scattering and concentration measurements |
| US10215683B2 (en) | 2015-11-02 | 2019-02-26 | Chiranjit Deka | Light scatter based apparatus and methods for hematology analysis using only three detectors |
| CN111158049B (en) * | 2019-12-27 | 2020-11-27 | 同济大学 | Seismic reverse time migration imaging method based on scattering integration method |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1092606A (en) * | 1976-10-05 | 1980-12-30 | Herbert Berger | 1-(n-acylcarbamoyl)-2-cyano-aziridines and the preparation thereof |
| US4284412A (en) | 1979-07-13 | 1981-08-18 | Ortho Diagnostics, Inc. | Method and apparatus for automated identification and enumeration of specified blood cell subclasses |
| US4661913A (en) * | 1984-09-11 | 1987-04-28 | Becton, Dickinson And Company | Apparatus and method for the detection and classification of articles using flow cytometry techniques |
| JPS64208A (en) * | 1987-06-22 | 1989-01-05 | Tanaka Kikinzoku Kogyo Kk | Production of fine gold particles |
| US5776709A (en) * | 1991-08-28 | 1998-07-07 | Becton Dickinson And Company | Method for preparation and analysis of leukocytes in whole blood |
| JP3320869B2 (en) * | 1993-12-22 | 2002-09-03 | シスメックス株式会社 | Leukocyte analysis reagent |
| US5547661A (en) * | 1994-02-22 | 1996-08-20 | Helene Curtis, Inc. | Antiperspirant deodorant compositions |
| JP3467310B2 (en) * | 1994-04-21 | 2003-11-17 | シスメックス株式会社 | Leukocyte analysis reagent and leukocyte classification method |
| US5939021A (en) | 1997-01-23 | 1999-08-17 | Hansen; W. Peter | Homogeneous binding assay |
| US6413786B1 (en) * | 1997-01-23 | 2002-07-02 | Union Biometrica Technology Holdings, Inc. | Binding assays using optical resonance of colloidal particles |
| US6114173A (en) * | 1997-04-03 | 2000-09-05 | Bayer Corporation | Fully automated method and reagent composition therefor for rapid identification and characterization of reticulocytes erythrocytes and platelets in whole blood |
| TWI251078B (en) * | 1999-03-29 | 2006-03-11 | Asahi Kasei Corp | Method for determining a white blood cell count of a whole blood sample, based on the concentration of myeloperoxidase |
| CA2440773A1 (en) * | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| AU2004308507A1 (en) * | 2003-12-19 | 2005-07-14 | Ark Diagnostics | Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics |
-
2004
- 2004-05-27 US US10/856,284 patent/US7611849B2/en not_active Expired - Fee Related
- 2004-05-27 WO PCT/US2004/016855 patent/WO2004106535A2/en active Application Filing
- 2004-05-27 AU AU2004243881A patent/AU2004243881B2/en not_active Ceased
- 2004-05-27 EP EP04753650A patent/EP1629109A4/en not_active Withdrawn
- 2004-05-27 CA CA002526868A patent/CA2526868A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| OLAVI SIIMAN: "Preparation, Microscopy, and Flow Cytometry with Excitation into Surface Plasmon Resonance Bands of Gold or Silver Nanoparticles on Aminodextran-Coated Polystyrene Beads", J. PHYS. CHEM. B, vol. 104, 2000, pages 9795 - 9810, XP008071161, DOI: doi:10.1021/jp000255z |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982193A2 (en) * | 2006-01-31 | 2008-10-22 | Point Care Technologies | Cell classification system |
| EP1982193A4 (en) * | 2006-01-31 | 2009-03-25 | Point Care Technologies | Cell classification system |
| US8889362B2 (en) | 2006-01-31 | 2014-11-18 | Point Care Technologies | Cell classification system |
| US20120312085A1 (en) * | 2007-09-17 | 2012-12-13 | Luminex Corporation | System, storage mediums, and methods for identifying particles in flow |
| US8570512B2 (en) * | 2007-09-17 | 2013-10-29 | Luminex Corporation | System, storage mediums, and methods for identifying particles in flow |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1629109A2 (en) | 2006-03-01 |
| AU2004243881B2 (en) | 2010-07-15 |
| US20040246480A1 (en) | 2004-12-09 |
| EP1629109A4 (en) | 2007-07-11 |
| WO2004106535A3 (en) | 2006-10-26 |
| CA2526868A1 (en) | 2004-12-09 |
| US7611849B2 (en) | 2009-11-03 |
| AU2004243881A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004243881B2 (en) | Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles | |
| KR0171452B1 (en) | Light scatter-based immunoassay without particle self aggregation | |
| EP0585369B1 (en) | Simultaneous multiple assays | |
| US6200820B1 (en) | Light scatter-based immunoassay | |
| AU695012B2 (en) | Immunoassay for determination of cells | |
| EP0788604B1 (en) | Method for preparing a sample in a scan capillary for immunofluorescent interrogation | |
| EP1023602B1 (en) | Protein-colloidal metal-aminodextran coated particle and methods of preparation and use | |
| JP6247643B2 (en) | Apparatus and method for performing hematological and biochemical measurements from biological samples | |
| EP0118894A2 (en) | Particle reagent size distribution measurements for immunoassay | |
| CA2733296A1 (en) | Use of focused light scattering techniques in biological applications | |
| EP0928420A1 (en) | Homogeneous binding assay | |
| WO2008035047A1 (en) | Blood typing | |
| US20180238876A1 (en) | Method For Assessing Cell Surface Receptors of Blood Cells | |
| WO2002077645A2 (en) | Method for the measurement of soluble analytes | |
| Hildén et al. | Flow‐cytometric quantitation of anti‐D antibodies | |
| KR101424720B1 (en) | A Novel Method for Measuring Platelet Activation and Apparatus Using It | |
| LIVESTOCK | A/tfK3sTl | |
| Cruse et al. | Immunologic Methods: Measurement of Antigens and Antibodies | |
| JPH07191031A (en) | Container and method for inspection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2526868 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004243881 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004753650 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2004243881 Country of ref document: AU Date of ref document: 20040527 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004243881 Country of ref document: AU |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004753650 Country of ref document: EP |